Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ALK |
| Variant | del exon4-11 |
| Impact List | deletion |
| Protein Effect | gain of function |
| Gene Variant Descriptions | ALK del exon4-11 indicates the deletion of exons 4-11 in the extracellular domain of the ALK gene (PMID: 23139213). Del exon4-11 does not demonstrate increased downstream pathway activation compared to wild-type ALK in one study, but confers a gain of function to Alk as demonstrated by increased kinase activity in an in vitro assay, increased proliferation and anchorage-independent growth in cultured cells, and tumor formation in a mouse model (PMID: 23139213), and in another study leads to increased downstream signaling and neurite outgrowth in cultured cells (PMID: 25251827). |
| Associated Drug Resistance | |
| Category Variants Paths |
ALK mutant ALK act mut ALK del exon4-11 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK del exon4-11 | neuroblastoma | sensitive | Lorlatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Lorbrena (lorlatinib) treatment inhibited proliferation of a neuroblastoma cell line harboring deletion of ALK exons 4-11 in culture and inhibited tumor growth in a cell line xenograft model (PMID: 27483357). | 27483357 |
| ALK del exon4-11 | neuroblastoma | sensitive | Entrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Rozlytrek (entrectinib) treatment inhibited ALK phosphorylation, downstream signaling, and viability of a neuroblastoma cell line harboring a deletion of ALK exons 4-11 in culture (PMID: 35085006). | 35085006 |